About ArtBlood
ArtBlood is a company based in Seoul (South Korea) founded in 2022. ArtBlood has raised $4.8 million across 1 funding round from investors including Partners Investment, Korea Development Bank Europe and Korea Investment Accelerator. ArtBlood operates in a competitive market with competitors including Hemotune, Medcura, ExThera Medical, Lindis Blood Care and CytoPherx, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.8 M (USD)
in 1 rounds
-
Latest Funding Round
$4.8 M (USD), Series A
Apr 09, 2024
-
Investors
Partners Investment
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ArtBlood
ArtBlood has successfully raised a total of $4.8M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.8 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ArtBlood
ArtBlood has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Partners Investment, Korea Development Bank Europe and Korea Investment Accelerator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in South Korea and the US
|
Locked | Locked | Locked | |
|
Startup acceleration services are provided by Korea Investment Accelerator.
|
Locked | Locked | Locked | |
|
Operates as a commercial bank providing deposits, loans, and payment services to customers.
|
Locked | Locked | Locked |
Investor details for ArtBlood
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ArtBlood
Investment portfolio details for ArtBlood
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ArtBlood
Detailed financials for ArtBlood
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Artblood Comparisons
Peer comparison for ArtBlood
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ArtBlood
ArtBlood operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemotune, Medcura, ExThera Medical, Lindis Blood Care and CytoPherx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of a device for blood purification
|
|
| Locked | Locked | Locked |
Developer of the device for controlling bleeding
|
|
| Locked | Locked | Locked |
Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking
|
|
| Locked | Locked | Locked |
Innovative solutions for safer blood transfusions are developed.
|
|
| Locked | Locked | Locked |
Cytopheresis systems for inflammatory conditions
|
Detailed competitors of ArtBlood
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Artblood
Complete news archive for ArtBlood
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ArtBlood
ArtBlood was founded in 2022 and raised its 1st funding round 2 years after it was founded.
ArtBlood is headquartered in Seoul, South Korea.
ArtBlood is a funded company, having raised a total of $4.8M across 1 funding round to date.
ArtBlood was founded in 2022 in Seoul, South Korea, within the biotechnology sector. A cell-based extracorporeal blood production system is developed by the company to generate red blood cells. These cells serve as reagents for detecting transfusion-related antibodies and as carriers for therapeutic agents and immunostimulants in treatments. Operations focus on advancing blood-related medical technologies for clinical and diagnostic uses.
ArtBlood's top competitors include Medcura, ExThera Medical and Lindis Blood Care.
ArtBlood has 5 investors. Key investors include Partners Investment, Korea Development Bank Europe, Korea Investment Accelerator, Heungkuk Securities, and One Law Partners.